

## Curriculum Vitae

**Kuan-Pin Su, M.D., Ph.D.**

E-mail: [cobolsu@gmail.com](mailto:cobolsu@gmail.com)

Date and Place of Birth: 13/6/1969, Tainan, Taiwan

### Current Position

- Chairman of Graduate Institute of Neural and Cognitive Sciences (CMU) (2014/08-)
- Professor of Psychiatry, School of Medicine & Institute of Neural and Cognitive Sciences, China Medical University (CMU) (2012/08-)
- Director, Mind-Body Interface Research Centre, China Medical University Hospital (2006/08-)
- Chief, Department of General Psychiatry, China Medical University Hospital (2002/3-)
- Honorary Faculty of Stress, Psychiatry and Immunology Laboratory (SPI-Lab), Institute of Psychiatry-King's College London (2008/11-)

### Professional Experience

1999/5-2002/3, Attending physician, Department of Psychiatry, Wan Fang Medical Centre & Taipei Medical University Hospital

### Education & Training

- 1988-1995, M.D., Kaohsiung Medical College, Kaohsiung, Taiwan
- 1995-1999, Chief Resident and Resident, Taipei City Psychiatric Centre
- 2005-2008, PhD, Institute of Psychiatry, King's College London, UK

### Awards

- 2013, Psychopharmacology Award from the British Association for Psychopharmacology (UK)
- 2013, GlaxoSmithKline Depression and Anxiety Research Award, Taiwanese Society of Psychiatry, Taiwan
- 2013, Professor Wen-Ho Chang Research Award, Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology, Taiwan
- 2012, Pacific Rim College of Psychiatrists: Young Psychiatrists Award
- 2012 and 2010, The International Society for the Study of Fatty Acids and Lipids (ISSFAL): New Investigator Award
- 2012, Teaching Excellency Award, China Medical University Hospital
- 2012, Psychiatric Research Society Annual Meeting Travel Award (USA)
- 2011, Thomson Reuters Research Front Award
- 2011, GlaxoSmithKline Depression and Anxiety Research Award, Taiwanese Society of Psychiatry, Taiwan
- 2011, Initiative Research Cooperation among Top Universities between UK and Taiwan, National Science Council, Taiwan
- 2011, Scientific Physician, China Medical University Hospital (CMUH)
- 2010, Ta-You Wu Memorial Award, National Science Council, Taiwan

- 2010, the Elite Physician of the Year, CMUH
- 2009 and 2004, the Best Physician of the Year, CMUH
- 2008, Professor Wen-Ho Chang Research Award, Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology, Taiwan
- 2008, Professor Robert Kerwin International Award from the British Association for Psychopharmacology (UK)
- 2008-2010, National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award (USA)
- 2007-2008, China Medical University Elite Faculty Scholarships
- 2007, Travel Award of the 20th ECNP
- 2006-2007, China Medical University Hospital Elite Scholarships
- 2006, Professor Janssen's Schizophrenia Research Award, Society of Psychiatry, Taiwan; Guided Tour Poster Nomination of the 19th European College Neuropsychopharmacology (ECNP); Travel Awards from King's College London; Travel Awards from Taipei Representative Office in the U.K.
- 2005-2006, Elite Program of Taiwan Merit Scholarships (TMS), Ministry of Education, Taiwan

## Research Grants

### Primary Investigator

- Pharmacogenomics of n-3 polyunsaturated fatty acids treatment for major depressive disorder: Genome-wide associations (2014-2017, NSC 103-2320-B-039-039-MY3)
- Major depression and omega-3 fatty acids: From cellular mechanisms to clinical implications (2014-2016, NSC-NCBR (National Centre for Research and Development, Poland) Joint Research Projects (NSC 103-2923-B-039 -002 -MY3)
- Omega-3 fatty acid on preventing depression in pregnant women (2013-2015, NSC-RS (Royal Society) Joint Research Projects 102-2911-I-039-501)
- Phospholipid hypothesis of depression: From molecular biology, neuroimaging to behaviour (2012-2015, Project for Excellent Junior Research Investigators NSC101-2628-B-039-001-MY3)
- Neuropsychobiology of Brain Theta-burst Stimulation: A Mind-body Interface for Depression (2012-2014, Innovative Research Grant (IRG) of Integrated Research Grants in Health and Medical Sciences from National Health Research Institutes NHRI-EX101-10144NI)
- The protective effect of astrocyte condition medium for glutamate-induced (2013-2014, China Medical University Hospital DMR-103-078)
- Genetic markers for interferon-alpha-induced depression in patients with chronic hepatitis C viral infection (2012-2013, China Medical University

- Hospital DMR-102-068)
- Heterogeneity of depression: The role of genetic variations in subtyping major depressive disorder (2011-2012, China Medical University Hospital DMR-101-081)
  - Neurocognitive and neurobiological mechanisms of interferon-induced depression (2009-2012, Integrated Research Project NSC 98-2627-B-039-003)
  - N-3 polyunsaturated fatty acids in the prevention and treatment for IFN-induced depression (2009-2012, NSC 98-2628-B-039-020-MY3)
  - The biological mechanism of n-3 polyunsaturated fatty acids in depression. Initiative Research Cooperation among Top Universities between UK and Taiwan (2010-2011, NSC 99-2911-I-039-002)
  - The biological mechanism of somatic symptoms in depression: The role of polyunsaturated fatty acids. National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award 2008-2010
  - Polyunsaturated fatty acids as biomarkers in classifying subtypes of depression (2008-2010, National Science and Technology Program for Biotechnology and Pharmaceuticals (NSTPBP) Translational Medicine Project, 97(2)-TRA-001)
  - Peripheral gene expression of PLA2 and COX2 in IFN-alpha-induced depression (China Medical University Hospital 2009-2010, DMR99-114)
  - The role of neurocognitive and neurobiological markers in interferon-induced depression: an exploratory study (China Medical University 2009-2010, CMU97-336)
  - The role of polyunsaturated fatty acids on sickness behaviour and depression induced by interferon therapy in patients with hepatitis C viral infection (2006-2009, NSC 95-2320-B-039-037-MY3)
  - Proteomic analysis in interferon-induced sickness behavior and depression in patients with hepatitis C viral infection (CMU95-143)
  - The effect of fish oil in bipolar disorder: a double-blind placebo-controlled trail for the antidepressant and maintenance effects of in bipolar disorder (2006-2008, DOH 95F022)
  - Effect of fish oil diet on rat's forced-swimming test (2005-2006, NSC 94-2314-B-039-027)
  - The effect of fish oil in major depressive disorder: a double-blind placebo-controlled monotherapy trail to demonstrate the therapeutic and preventive effects of depression (2005-2008, DOH 94F044)
  - Omega-3 polyunsaturated fatty acids in women with major depressive disorders during pregnancy and afterbirth: from the perspectives of epidemiology, membrane psychopathophysiology, dietary differences and the double-blind placebo-controlled therapeutic trail (2002-2005, NSC

- 91-2320-B-039-017, 92-2320-B-039-003, 93-2320-B-039-001)
- Omega 3 fatty acids in schizophrenic disorder: from the perspectives of the double-blind placebo-controlled therapeutic trial, membrane psychopathophysiology, and dietary differences (2001-2004, NSC 90-2320-B-038-046, 91-2320-B-039-010, 92-2320-B-039-002)
  - Omega 3 fatty acids in major depressive disorder: the composition of Omega 3 PUFAs in red cell membrane & parallel-group, double blind, placebo-controlled therapeutic trial (2000, NSC 89-2320-B-038-046)
  - Omega 3 fatty acids in major depressive disorder: parallel-group, double blind, placebo-controlled trial (1999, Taipei Medical College, TMC88-Y05-A121)
  - Lipid, glucose and leptin abnormalities induced by novel antipsychotic drugs (2003-2004, China Medical University Hospital, DMR-92-017)
  - Effect of omega-3 fatty acid diet on rat's depressive-like behaviors in forced-swimming test (2004-2005, China Medical University, CMU93-M-24)
  - Effect of omega-3 fatty acid diet on rat's reserpine-induced depressive-like behaviours (2005-2006, China Medical University, CMU94-105)

#### **Co-Investigator**

- The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO) (3-year, JSPS 25702043 from the Japan Society for the Promotion of Science)
- Production of srpk2 knockout mice and exploring the mechanisms of the pathogenesis. (NSC 102-2320-B-039-039)
- The biological mechanisms of n-3 polyunsaturated fatty acid treatment in interferon-induced depression (NSC 101-2320-B-038-020-MY2)
- The study of polymorphisms and expressions in genes of omega-3 fatty acid metabolism enzymes in the patients with major depressive disorder. (3 years, NSC 98-2320-B-038-018-MY3)
- The study of effects of antidepressant treatment on leukocyte-platelet interaction in medically health patients with major depressive disorder. (3 years, NSC 98-2314-B-039-011-MY3)
- Investigation of the effects of water extract from *Gastrodia elata* Blume on its antidepressant mechanisms in animal models and clinical study (CCMP95-RD-033)
- Functional MRI for depressive patients before and after received antidepressants with different mechanism (2 years, NSC 94-2314-B-039-011, NSC 95-2314-B-039-003)
- The study of fingerprint fluctuating asymmetry criterions on schizophrenia (NSC 92-2320-B-039-020)

- Omega-3 fatty acids added to clozapine for patients with schizophrenia. (NSC 92-2314-B-109-003)
- Omega-3 polyunsaturated fatty acids with the risk of Alzheimer's disease and its cognitive effects of supplementation (DOH92-TD-1095)
- Weight gain and dyslipidemia induced by atypical antipsychotics: mechanism investigation and treatment by omega-3 fatty acids. (NSC 91-2314-B109-003)
- The validation of the Taiwanese version of the Edinburgh Postnatal Depressive Scale (EPDS) for major depressive disorder during pregnancy and afterbirth. (China Medical University Hospital, DMR-92-92)
- Predictors and Prevalence of Depressive Symptoms in Antenatal and Postpartum Women. (China Medical University Hospital, DMR-94-46)

**Reviewer for the International Journals and Funding Bodies**

**International project reviewer** (more than 30 proposals): China Medical University (since 2002), Department of Health, Taiwan (since 2008), Ontario Mental Health Foundation, Canada (2010), National Forensic Mental Health R&D Programme, UK (2004), National Science Council (NSC, since 2002), Taipei Veteran Hospital (2009), Tzu Chi University (since 2002)

**Journal reviewer** (more than 70 papers): Acta Psychiatrica Scandinavica (since 2005), American Journal of Clinical Nutrition (2009), Biological Psychiatry (since 2005), Bipolar Disorders (since 2006), British Journal of Nutrition (since 2006), Cellular and Molecular Neurobiology (since 2010), Clinical Drug Investigation (2012), Clinical Medicine: Psychiatry (2008), European Neuropsychopharmacology (since 2008), Journal of Affective Disorders (since 2009), Journal of Clinical Psychiatry (2010), Journal of Experimental and Clinical Medicine (2010), Journal of Formosan Medical Association (since 2008), Journal of Neurochemistry(2009), Journal of Psychiatric Research (2010), Journal of Psychopharmacology (since 2008), Journal of Psychiatry and Neuroscience (2006), Journal of Psychosomatic Research (2010), Lipid Insights (2008), Mid-Taiwan Journal of Medicine (2003), Molecular Psychiatry (2012), Neuropsychopharmacology (2010), Progress in Neuro-Psychopharmacology & Biological Psychiatry (since 2007), Psychological Medicine (since 2007), Psychiatric Research (since 2006), Psychiatry Investigation (since 2012), Psychosomatics (2002), Psychosomatic Medicine (since 2008), Psychotherapy and Psychosomatics (2012), Schizophrenia Research (since 2006), Taiwan Geriatrics & Gerontology (2009), Taiwanese Journal of Psychiatry (since 2007), Tzu Chi Medical Journal (since 2002)

**Committee, Membership &**

- Chairman, the 1st-4th Mind-Body Interface International Symposium (2010, 2011, 2013, 2014)

## **Certification**

- Editorial board member of the Psychiatry Investigation (since 2012)
- International Affair Committee of the Taiwanese Society of Suicidality (since 2010)
- Executive editor of the Taiwanese Journal of Psychiatry (since 2009)
- Asia Consortium member of the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) (since 2009)
- Membership of the British Association for Psychopharmacology (since 2007)
- Membership of the European College of Neuropsychopharmacology (since 2007)
- Membership of the International Society for Bipolar Disorders (since 2005)
- Editorial Board of the Bipolar Disorders Update (since 2006)
- Member of Organizing Committee, DEPRESSION: BRAIN CAUSES, BODY CONSEQUENCES, Royal Society of Medicine, Institute of Psychiatry, King's College London, UK (2007/4/2-3)
- Taiwanese Psychiatric Association (#000585)
- Taipei Medical Association (#16258)
- The Higher Civil Service Examination Certification (#026430)

## **Publication**

- See next page

## Publications

### (1) Referred Paper

1. Chen WC, Lai HC, Su WP, Palani M, Su KP. Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study. **Psychiatry Investig**. 2015 Jan;12(1):142-5.
2. Chang JP, Chang SS, Yang HT, Palani M, Chen CP, Su KP\*. Polyunsaturated fatty acids (PUFAs) levels in patients with cardiovascular diseases (CVDs) with and without depression. **Brain Behav Immun** 2014 Nov 20.
3. Su KP, Lai HC, Yang HT, Su WP, Peng CY, Chang JPC, Huang CL, Chang HC, Pariante CM. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression Results from a randomized, controlled trial. **Biological Psychiatry** 2014 Oct 1; 76 (7):559-66.
4. Chang JPC, Lin CC, Hwu HG, Su KP\*. View on DSM from Taiwan: Transition from IV to 5. **Acta Psychiatrica Scandinavica** 2014 Mar; 129(3): 235.
5. Talarowska M, Bobińska K, Zajączkowska M, Su KP, Maes M, Galecki P. Impact of oxidative/nitrosative stress and inflammation on cognitive functions in patients with recurrent depressive disorders. **Medical Science Monitor** 2014 Jan; 20: 110-5.
6. Su KP, Wang SM, Pae CU. Omega-3 polyunsaturated fatty acids for major depressive disorder. **Expert Opinion On Investigational Drugs** 2013 Dec; 22(12): 1519-1534.
7. Chang JPC, Lin CC, Hwu HG, Su KP. View on DSM from Taiwan: Transition from IV to 5. **Acta Psychiatrica Scandinavica** in press.
8. Talarowska M, Bobińska K, Zajączkowska M, Su KP, Maes M, Galecki P. Impact of oxidative/nitrosative stress and inflammation on cognitive functions in patients with recurrent depressive disorders. **Medical Science Monitor** in press.
9. Lu DY, Leung YM, Su KP\*. Interferon- $\alpha$  induces nitric oxide synthase expression and heme oxygenase-1 down-regulation in microglia: Implications of cellular mechanism of IFN- $\alpha$ -induced depression. **International Journal of Neuropsychopharmacology** 2013 Mar; 16(2): 433-44.
10. Lin PY, Mischoulon D, Freeman MP, Matsuoka Y, Hibbeln J, Belmaker RH, Su KP\*. Are omega-3 fatty acids anti-depressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. **Molecular Psychiatry** 2012 Dec; 17(12): 1161-3.
11. Chen WC, Lai HC, Su WP, Palani M, Su KP. Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: An open-label study. **African Journal of Psychiatry** Accepted.
12. Tseng YL, Chiang ML, Lane HY, Su KP, Lai YC. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation. **Thromb Res**. 2013 Apr; 131(4): 325-32.
13. Lin PY, Chiu CC, Huang SY, Su KP\*. A meta-analytic review of polyunsaturated fatty acid compositions in dementia. **Journal of Clinical Psychiatry** 2012; 73(9): 1245-1254.
14. Su KP. Inflammation in psychopathology of depression: Clinical, biological, and therapeutic implications. **BioMedicine** 2012 June; 2(2): 68-74.
15. Chang HC, Tang CH, Huang ST, McCrone P, Su KP\*. A cost-consequence analysis of long-acting

injectable risperidone in schizophrenia: a one-year mirror image study with national claim-based database in Taiwan. **Journal of Psychiatric Research** 2012 Jun; 46(6): 751-6.

16. Liang JA, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, Kao CH. A nationwide population-based cohort study: Anxiety disorders will increase subsequent cancer risk? **PLoS ONE** 2012 April; 7(4): e36370, 1-6.
17. Kao CH, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, Liang JA. Use of benzodiazepine increases cancer risk – A population-based cohort study in Taiwan. **Journal of Clinical Psychiatry** 2012 April; 73(4): 555-560.
18. Jadoona A, Chiu CC, McDermott L, Cunningham P, Frangou S, Chang CJ, Sun YW, Liu SI, Lu ML, Su KP, Huang SY, Stewart R. Associations of polyunsaturated fatty acids with residual depression or anxiety in older people with major depression. **Journal of Affective Disorder** 2012 Feb;136(3): 918-25.
19. Chen YT, Su KP, Chang J. Early detection and management of atypical Neuroleptic malignant syndrome secondary to aripiprazole. **Schizophrenia Research** 2011 Sep; 132(1): 97-98.
20. Chen PJ, Liang KC, Lin HC, Hsieh CL, Su KP, Hung MC, Sheen LY. Gastrodia elata Bl. Attenuated Learning Deficits Induced by Forced-Swimming Stress in the Inhibitory Avoidance Task and Morris Water Maze. **J Med Food** 2011 Jun; 14(6): 610-7.
21. Guu TW, Su KP\*. Musical creativity and mood bipolarity in Robert Schumann- A tribute to the 200th anniversary of the composer's birth. **Psychiatry and Clinical Neuroscience** 2011; 65: 112-114.
22. Chang J, Wu CC, Su KP\*. A case of venlafaxine-induced bruxism alleviated by duloxetine substitution. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2011; 35: 307.
23. Tseng YL, Chiang ML, Huang TF, Su KP, Lane HY, Lai YC. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. **Thrombosis Research** 2010 Dec; 126(6): 517-523.
24. Lu DY, Tsao YY, Leung YM, Su KP\*. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: Implications of antidepressant effects for omega-3 fatty acids. **Neuropsychopharmacology** 2010 Oct; 35(11): 2238–2248.
25. Wu CC, Chang J, Liou JS, Su KP\*. A case of milnacipran-induced sweating alleviated by duloxetine substitution. **Journal of Clinical Psychopharmacology** 2010 Oct; 30(5): 640-1.
26. Chang J, Su KP\*. The lipid raft hypothesis: the relation among omega-3 fatty acids, depression and cardiovascular diseases. **Taiwanese Journal of Psychiatry** 2010 Sep; 24(3): 168-80.
27. Lin PY, Huang SY, Su KP\*. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. **Biological Psychiatry** 2010 Jul 15;68(2):140-147.
28. Wu CC, Tsai CH, Lu MK, Chen CM, Shen WC, Su KP\*. Theta-burst repetitive transcranial magnetic stimulation for treatment-resistant obsessive-compulsive disorder with concomitant depression. **Journal of Clinical Psychiatry** 2010 April; 71(4): 504-506.
29. Su KP, Huang SY, Peng CY, Lai CH, Huang CL, Chen YC, Aitchison KJ, Pariante CM. Phospholipase A2 and cyclo-oxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. **Biological Psychiatry** 2010 Mar; 67(6): 550-557.



30. Chang J, Wu CC, Su KP\*. Paliperidone overdose in a patient with schizophrenia. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2010 Mar; 34(2): 418.
31. Su KP\*, Chang HC\*, Tsai SJ, Tang CH. Relapse and long-acting injectable risperidone: A one-year mirror image study with a national claims database in Taiwan. **Value in Health** 2009; 12(S3): S118-S121.
32. Su KP. The biological mechanism of antidepressant effect of omega-3 fatty acids: How does fish oil acts as a “mind-body interface?” **NeuroSignals** 2009 Feb; 17(2): 144-152.
33. Chang HC, Tang CH, Tsai SJ, Yen FC, Liu JP, Su KP\*. Long-acting injectable risperidone and hospital readmission: A mirror image study with a national claim-based database in Taiwan. **Journal of Clinical Psychiatry** 2009 Jan; 70(1): 141.
34. Chen PJ, Hsieh CL, Su KP, Hou YC, Chiang HM, Sheen LY. Rhizomes of *Gastrodia elata* B(L) Possess Antidepressant-Like Effect via Monoamine Modulation in Subchronic Animal Model. **Am J Chin Med** 2009; 37(6): 1113-24.
35. Chang J, Wu PL, Lane HY, Su KP\*. Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment for Isaacs Syndrome with Depression. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2009 Jun 15; 33(4): 739-40.
36. Chang J, Chen YT, Su KP\*. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) in cardiovascular diseases (CVD) and depression: the missing link? **Cardiovascular Psychiatry and Neurology** 2009(2009), Article ID 725310, 6 pages. doi:10.1155/2009/725310. (\*Correspondence).
37. Wu CC, Su KP. Quetiapine-induced Rabbit Syndrome in a patient with bipolar disorder. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2008 Dec; 32(8):2002-3.
38. Chiu CC, Liu JP, Su KP\*. The use of omega-3 fatty acids in treatment of depression: the lights and shadows. **Psychiatric Times** 2008 Aug; 25(9): 76-80.
39. Su KP\*, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. **Journal of Clinical Psychiatry** 2008 Apr; 69(4): 644-651.
40. Chiu CC, Su KP, Cheng TC, Liu HC, Stewart R, Huang SY. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2008; 32(6): 1538–1544.
41. Liao CC, Huang CL, Chang YH, Lin CC, Su KP\*. Red Yeast Rice for a patient with olanzapine-induced dyslipidemia: a test-and-retest case report. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2008 Jul; 32(5): 1340-1341.
42. Wang JF, Lin CL, Chang YH, Chen TY, Su KP, Nagurka ML. Determining the association between dermatoglyphics and schizophrenia by using fingerprint asymmetry measures. **International Journal of Pattern Recognition and Artificial Intelligence** 2008; 22(3): 601-616. [EI]
43. Chen PJ, Hsieh CL, Su KP, Hou YC, Chiang HM, Lin IH, Sheen LY. The Antidepressant Effect of *Gastrodia elata* Bl. on the Forced-Swimming Test in Rats. **American Journal of Chinese Medicine** 2008 Jan; 36(1): 95-106.
44. Su KP\*. Mind-body interface: The role of n-3 fatty acids in psychoneuroimmunology, somatic

presentation, and medical illness comorbidity of depression. **Asia Pacific Journal of Clinical Nutrition** 2008 Jan; 17(S1): 147-153.

45. Huang SY, Yang HT, Chiu CC, Pariante C, Su KP\*. Omega-3 fatty acids on the forced-swimming test. **Journal of Psychiatric Research** 2008 Jan; 42(1): 58-63.
46. Su KP\*, Chiu TH, Huang CL, Ho M, Lee CC, Wu PL, Lin CY, Liao CH, Liao CC, Chiu WC, Pariante CM. Different cut-off points for different trimesters? The use of Edinburgh Postnatal Depression Scale and Beck Depression Inventory to screen depression during pregnancy in Taiwan. **General Hospital Psychiatry** 2007 Sep-Oct; 29(5): 436-41.
47. Lin PY, Su KP\*. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. **Journal of Clinical Psychiatry** 2007 Jul; 68(7): 1056-1061.
48. Wu PL, Liao KF, Peng CY, Pariante CM, Su KP\*. Manic episode associated with citalopram therapy for IFN-induced depression in a patient with chronic hepatitis C infection. **General Hospital Psychiatry** 2007 Jul-Aug; 29(4): 374-6.
49. Huang CL, Su KP\*, Hsu HB, Pariante C. A pilot crossover study on QTc interval associated with olanzapine and risperidone. **Journal of Clinical Psychiatry** 2007 May; 68(5): 803-5.
50. Lin CY, Wu PL, Pariante C, Su KP\*. A crossover study on prolactin changes associated with risperidone and olanzapine. **Journal of Clinical Psychiatry** 2006 Sep; 67(9): 1470-1471.
51. Liao CH, Shen WW, Su KP\*. Venlafaxine-associated serotonin syndrome and manic episode in a geriatric depressive patient. **Psychiatry and Clinical Neuroscience** 2006; 60(1): 121-122.
52. Wu PL, Lane HY, Su KP\*. Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus. **Psychiatry and Clinical Neuroscience** 2006; 60(1): 115-116.
53. Chiu CC, Huang SY, Chen CC, Su KP\*. Omega-3 fatty acids is more beneficial to depression than to mania in patients with bipolar I disorder. **Journal of Clinical Psychiatry** 2005 Dec; 66(12): 1613-14.
54. Su KP\*, Wu PL, Pariante C. A crossover study on of lipid and weight changes associated with olanzapine and risperidone. **Psychopharmacology** 2005 Dec; 183(3):383-386.
55. Huang SY, Chiu CC, Shen WW, Chang HC, Su KP\*. Hypoalbuminemia in drug-free patients with major depressive disorder compared with a dietary matched control group: A clinical meaning beyond malnutrition. **European Neuropsychopharmacology** 2005; 15(2): 227-230.
56. Chiu CC, Huang SY, Su KP\*. Omega-3 polyunsaturated fatty acids for postpartum depression. **American Journal of Obstetrics and Gynecology** 2004; 190 (2): 582-583.
57. Su KP, Chuang CL, Chen KP, Lane HY, Shen WW. Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome. **Schizophrenia Research** 2004; 66 (2-3): 191-192.
58. Huang SY\*, Wu SS, Chiu CC, Kuo CJ, Su KP, Lu ML. Assessment of Dietary Intake and Blood Fatty Acid Composition in Patients with Schizophrenia. **Nutrition Science Journal** 2004; 29(1): 21-30. [Full text in Chinese]
59. Su KP\*, Huang SY\*, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. **European Neuropsychopharmacology** 2003; 13(4): 267-271.

60. Chiu CC, Huang SY, Su KP\*, Lu ML, Huang MC, Chen CC, Shen WW. Polyunsaturated fatty acid deficit in patients with bipolar mania. **European Neuropsychopharmacology** 2003; 13(2): 99-103.
61. Chiu CC, Huang SY, Shen WW, Su KP\*. Omega-3 fatty acid monotherapy for a pregnant patient with major depressive disorder. **American Journal of Psychiatry** 2003; 160(2): 385. **[Erratum on affiliation: American Journal of Psychiatry 2003; 160 (4): 801]**
62. Su KP, Chuang CL, Chen KP, Chen CC, Shen WW. A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol use. **Schizophrenia Research** 2003; 59(1): 93-34.
63. Su KP, Leu SYC, Yang YY, Shen WW, Chou YM, Tsai SYM. The change of interferon-gamma and interleukine-10 in bipolar mania and subsequent remission. **Journal of Affective Disorder** 2002; 71: 205-9. **[Erratum on affiliation: Journal of Affective Disorder 2003; 73: 299]**
64. Lu ML, Pan JJ, Teng HW, Su KP, Shen WW. Metoclopramide-Induced supersensitivity psychosis. **Annals of Pharmacotherapy** 2002; 36: 1387-90.
65. Su KP, Chang HC, Shen WW. QTc Prolongation associated with haloperidol, risperidone and ziprasidone. **American Journal of Psychiatry** 2002; 159: 1062-1063.
66. Pan CC, Shen WW, Su KP\*. Individual psychotherapy for transsexualism with the co-morbidity of depressive disorder - 3 cases reports. **Taiwanese Journal of Psychiatry** 2002; 16(3): 237-242.
67. Su KP, Huang SY, Shen WW. Brief review on lipid abnormalities induced by novel antipsychotic drugs. **Drug Safety** 2001; 24 (13): 1017-8.
68. Su KP, Shen WW, Huang SY. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. **European Neuropsychopharmacology** 2001; 11(4): 295-299.
69. Su KP, Hsu CY, Hsieh SC, Shen WW. Magnetic resonance imaging findings in patients with delusional disorder due to diffuse cerebrovascular disease: a report of seven cases. **Psychiatry and Clinical Neuroscience** 2001; 55(2): 121-126
70. Hsieh WC, Shen WW, Pan CC, Su KP\*. Intensive stress-management Group psychotherapy on outpatients with anxiety disorders: a pilot demonstration. **Taiwanese Journal of Psychiatry** 2001; 15(2): 117-125.
71. Su KP, Yu JM, Yang TW, Tsai SY, Chen CC. Mentally retarded criminal offenders in northern Taiwan. **Journal of Forensic Science** 2000; 45(6): 1207-1209
72. Su KP, Huang SY, Shen WW. Effects of polyunsaturated fatty acids on psychiatric disorders. **American Journal of Clinical Nutrition** 2000; 72(5): 1241
73. Shen WW, Su KP. Torsadogenicity and antipsychotic drugs. **Taiwanese Journal of Psychiatry** 2000; 14(3): 6-22.
74. Su KP, Huang SY, Shen WW. Is omega 3 fatty acids beneficial in depression but not mania? **Archives of General Psychiatry** 2000; 57(7): 716.
75. Su KP, Tsai SY, Huang SY. Cholesterol, depression and suicide. **British Journal of Psychiatry** 2000; 176(4): 399.
76. Su KP, Lee HC, Pan CC, Tsai SY. The screening of depressed mood in the elderly Taiwanese. **New Taipei Journal of Medicine** 2000; 2(2): 81.

77. Su KP, Lee HC, Pan CC, Huang SY. Lipid and psychiatric disorders: Does total serum cholesterol matter? **Taiwanese Journal of Psychiatry** 2000; 14(1): 77-9.
  78. Su KP, Lee YJ, Lee MB. Severe peripheral polyneuropathy and rhabdomyolysis in lithium intoxication: a case report. **General Hospital Psychiatry** 1999; 21(2): 136-7.
  79. Lane HY, Su KP, Chang WH. Seizures after Discontinuation of Low-Dose Lorazepam From Originally Seizure-Free Clozapine Regimen: Combined Effects? **Journal of Clinical Psychiatry** 1999; 60(6): 408-409.
  80. Lane HY, Su KP, Chang WH. Elevated plasma clozapine concentrations after phenobarbital discontinuation. **Journal of Clinical Psychiatry** 1998; 59(3): 131-3.
- **SCI: 66** (first author: 22, \*Correspondence author: 30)
  - **Non-SCI: 9** (first author: 3, Correspondence author: 4)

## (2) Book chapter

1. Su KP, Balanzá-Martínez V. Role of omega-3 fatty acids in mood disorders (Chapter 16). In McNamara RK, Editor. *The omega-3 fatty acid deficiency syndrome: opportunities for disease prevention*. Nova Science Pub Inc., NY, USA: 2013, pp. 315-336 (ISBN 978-1-62417-703-3).
2. Chang JPC, Su KP. Omega-3 polyunsaturated fatty acids (PUFAs) as the “Mind-Body Interface” in cardiovascular diseases and depression. In: Rodriguez-Cruz M, Editor. *The latest finding of the long chain polyunsaturated fatty acids: since molecular mechanism to new application in the health*. Bentham Science Publishers, Bussum, Netherlands: 2011, pp. 58-66. (ISBN 978-1-60805-356-8)
3. Su KP, Shen WW, Huang SY. The use of omega-3 fatty acids for the management of depression and psychosis during pregnancy and breast-feeding. In: Peet M, Glen I, Horrobin DF, Editors. *Phospholipid spectrum disorder in psychiatry and neurology*, 2nd ed. Marius Press, 2003, Carnforth, UK: pp. 391-399. (ISBN 978-1871622256)

## (3) Conference Paper

1. Su KP\*. Health service utilization and long-acting injectable antipsychotic treatment: results from the national claim-based database in Taiwan. Symposium of Phase Specific Treatment of Schizophrenia with Christoph, Taishiro & Kane. The 3rd Asian College of Neuropsychopharmacology (AsCNP), Beijing, China, 11th-14th, September, 2013 (Invited Speaker)
2. Su KP\*. Omega-3 fatty acids in depression: The biological, therapeutic and preventive implications. The Annual Meeting of British Association for Psychopharmacology (BAP), Harrogate, UK, 28 - 21 July, 2013. (**BAP Psychopharmacology Award**, Invited Speaker)
3. Su KP\*. Mind-Body Interface: Omega-3 fatty acids in the prevention of interferon-alpha-induced depression, The 11th World Congress of Biological Psychiatry, in Kyoto, Japan, 23 - 27 June 2013 (Invited Speaker)
4. Su KP\* & Yutaka Matsuoka. Overview of Nutritional Psychiatry. The 1st International Society of Nutritional Psychiatry Research (ISNPR), at the National Institute of Health and Nutrition in Tokyo, Japan, 21st June, 2013 (Symposium Chairs)
5. Su KP\*. Omega-3 in depression: the biological, therapeutic and preventive implications, The 1st International

Society of Nutritional Psychiatry Research (ISNPR), at the National Institute of Health and Nutrition, Tokyo, Japan, 21st June, 2013 (Invited Speaker)

6. Su KP\*. Omega-3 fatty acids in depression: The biological, therapeutic and preventive implications. The Global Omega-3 Summit 2013, Crowne Plaza Le Palace, Brussels, Belgium, 30th May, 2013 (Invited keynote speaker).
7. Su KP\*. Omega-3 fatty acids in the prevention of interferon-induced depression. The CINP Thematic Meeting on Personalised Medicine, Jerusalem, Israel, 21-23, April, 2013 (Invited Speaker)
8. Su KP\*. Omega-3 fatty acids in psychiatric disorders: The clinical, neurobiological, and therapeutic implications. The 3rd Annual Meeting of Japan Society for Mental Health and Nutrition, Tokyo, Japan, 11th November, 2012 (Invited keynote speaker)
9. Su KP\*. Are we all the same? Needs for psychiatric research collaboration for Asian psychiatrists. The 15th Pacific Rim College of Psychiatrists Scientific Meeting, Seoul, South Korea, 25-27 October, 2012 (**Young Psychiatrists Travel Award**, Invited Speaker)
10. Su KP\*, Yang HT, Chang JPC, Huang CL, Pariante C. Mind-body interface: Omega-3 fatty acids in somatic symptoms in depression, The 10th International Society for the Study of Fatty Acids and Lipids (ISSFAL), Vancouver, Canada, 26 May-30, 2012 (**New Investigator Award**, Invited Speaker)
11. Su KP\*, Chang HC, Tang CH. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror image study with national claim-based database in Taiwan. The 28th Biennial World Congress of International College of Neuropsychopharmacology (CINP), 3-7, June, 2012, Stockholm, Sweden. (Poster Presentation)
12. Su KP\*. Prediction and prevention of INF-induced depression: The role of omega-3 fatty acids, Annual Meeting of Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology, 2012/05/19 (Sat), Taipei, Taiwan (**Research Award**, Invited Speaker)
13. Su KP\*. Deconstruct anxiety and depression: Fear and hopelessness in neurosciences. The 30th Anniversary Scientific Symposium of the Veteran General Hospital and the Neurology Submit, 2012/05/06, Taichung, Taiwan (Invited Speaker)
14. Su KP\*. Chair of the talks by Professors Hsien-Yuan Lane (Title: NMDA Modulation in CNS disorders) and Wolfgang Sattler (Title: Myeloperoxidase-mediated alterations of plasmalogen homeostasis induce blood-brain barrier dysfunction) in International Symposium in Commemoration of the 5th Anniversary of College of Life Sciences, China Medical University, 2012/5/4-5, Taichung, Taiwan (Chairman)
15. Su KP\*. Trends of neuroscience research in depression. The Fourth Annual Symposium of the Graduate Institute of Neural and Cognitive Sciences, China Medical University, 2012/5/4, Taichung, Taiwan (Invited Speaker)
16. Su KP\*. Polyunsaturated Fatty Acids and Somatic Symptoms in Major Depressive Disorder, 2012/02/08-11, 2012 Psychiatric Research Society, Park City, Utah, USA (**PRS Travel Award**, Invited Speaker)
17. Su KP\*. Are we all the same? Needs for biological and clinical research focusing on East Asians, 2011/11/3-5, The World Psychiatry Association (WPA) Regional Meeting, Kaohsiung, Taiwan (Invited Speaker)
18. Su KP\*. Mind-body interface: Omega-3 fatty acids in somatic anxious symptoms in depression, 2011/11/3-5, The World Psychiatry Association (WPA) Regional Meeting, Kaohsiung, Taiwan (Invited Speaker)
19. Su KP\*. Chair of the Symposium “Omega-3 fatty acids in depression and anxiety: from bench to bedside”, 2011/11/3-5, The World Psychiatry Association (WPA) Regional Meeting, Kaohsiung, Taiwan (Chairman)

20. Su KP\*. Mind-Body Interface: Omega-3 fatty acids in somatic symptoms in depression, Global Symposium on Affective Disorder: Collaboration between clinical research and practice, 2011/10/21-22, Keio University, Tokyo, Japan (Invited Speaker)
21. Su KP\*. Omega-3 fatty acids in physical symptoms in depression, in Symposium #13 “Omega-3 fatty acids in depression and anxiety: from bench to bedside”, The 2nd Congress of the Asian College of Neuropsychopharmacology, 2011/9/23-24, Seoul, Korea (Invited Speaker)
22. Su KP\*. Chair of the “Omega-3 fatty acids in depression and anxiety: from bench to bedside (Symposium 13)”, The 2nd Congress of the Asian College of Neuropsychopharmacology, 2011/9/23-24, Seoul, Korea (Chairman)
23. Su KP\*. Mind-Body Interface: Omega-3 fatty acids in somatic symptoms in depression, from Symposium 25 "Fish oil and depression from cellular mechanisms to clinical care", the 10th World Congress of Biological Psychiatry, 2011/05/30-6/2, Prague, Czech (Invited Speaker)
24. Su KP\*. The preclinical and clinical rationale for the development of newer antipsychotics, a keynote speaker for ASEAN Workshop on Schizophrenia, February 13th, 2011, Singapore Psychiatric Association, Singapore (Plenary Keynote Speech)
25. Su KP\*. Modulator for the round-table session about “Adjunctive antipsychotics in MDD: when current treatments are not enough”, speakers including Ashwin Patkar (USA), Chi-Un Pae (Korea), Chang su Han (Korea), Chia-Ming Chang (Taiwan), March 25th, 2011, OPTIMUM Forum by OIAA, Otsuka, Guilin, China
26. Su KP\*. Mind-Body Interface: The role of n-3 fatty acids in psycho-immunology in depression. The 1st Mind-Body Interface International Symposium for the 30th Anniversary of China Medical University Hospital, Taichung, Taiwan, November 5th, 2010. (Invited Speaker)
27. Su KP\* Tsao YY, Leung YM, Lu DY. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia. The 23rd European College Neuropsychopharmacology, Amsterdam, the Netherlands, 28th August-1st September, 2010.
28. Su KP\*, Huang SY, Peng CY, Lai HC, Huang CL, Cheng JC, Aitchison KJ, Pariante C. The effects of polymorphisms in phospholipase A2 and cyclo-oxygenase 2 genes on interferon-alpha-induced depression and polyunsaturated fatty acids levels. The 9th International Society for the Study of Fatty Acids and Lipids (ISSFAL), Maastricht, The Netherlands, 29 May – 2 June, 2010; **New Investigator Award**
29. Su KP\*. Omega-3 Fatty Acids as Mind-Body Interface in Depression: From Clinics to Cells. The 2nd World Congress of Asian Psychiatry (WCAP), Taipei, Taiwan, November 7th-10th, 2009. (Invited Speaker)
30. Su KP\*, Peng CY, Lai HC, Huang SY, Aitchison KJ, Pariante C. Polyunsaturated fatty acids and interferon-alpha-induced depression. The Annual Meeting of Biological Psychiatry, Vancouver, Canada, 14-16 May, 2009. (Citation: BIOL PSYCHIATRY 2009;65: 69S)
31. Su KP\*, Huang SY, Peng CY, Liao KF, Lai HC, Huang CL, Cheng JC, Aitchison KJ, Pariante C. Polyunsaturated fatty acids and interferon-alpha-induced depression. The Annual Meeting of British Association for Psychopharmacology (BAP), Harrogate, UK, 20 – 23 July, 2008. (Citation: Journal of Psychopharmacology 2008, Volume 22 (s5), Page A74; **Professor Robert Kerwin International Award**)
32. Su KP\*, Huang SY, Chiu TH, Huang CL, Pariante C. 342. Omega-3 fatty acids on major depressive disorder during pregnancy. The 62nd annual meeting of the Society of Biological Psychiatry Association, 1-3, May, 2008, Washington, U.S.A. (Citation: BIOL PSYCHIATRY 2008;63:1S-301S).
33. Su KP\*. Brain-Body Interface: Omega-3 Fatty Acids in Physical Diseases and Depressive Disorders. Invited

Speaker: The 10th Asian Congress of Nutrition (10th ACN), Taipei, Taiwan, September 9th-13th, 2007. (Invited Speaker)

34. Su KP\*, Peng CY, Cheng JC, Pariante C. Polymorphisms in cytosolic phospholipase A2 and cyclooxygenase 2 genes and risk of interferon-induced depression. The 20th European College Neuropsychopharmacology, 14th-17th, October, 2007, Vienna, Austria. (Citation: European Neuropsychopharmacology, Volume 17, Supplement 4, Page S334-335; **ECNP Travel Award**)
35. Su KP\*, Peng CY, Liao KF, Lai HC, Huang CL, Cheng JC, Aitchison KJ, Pariante CM. Polymorphisms in cytosolic phospholipase A2 and cyclooxygenase 2 Genes and risk of interferon-induced depression. The 61st annual meeting of the Society of Biological Psychiatry Association, 17-19, May, 2007, San Diego, California, U.S.A. (BIOL PSYCHIATRY 2007;61:235S; **Travel awarded by King's College London**)
36. Su KP\*, Chiu CC, Huang SY. Omega-3 fatty acids on FST. The Second Dual Congress, the European Congress of the International Neuropsychiatric Association and the Mediterranean Congress of the World Federation of Societies of Biological Psychiatry, 7-10 December 2006, Athens, Greece (**Travel awarded by King's College London**).
37. Su KP\*, Huang CL, Hsu HB, Pariante C. A pilot crossover study on QTc interval associated with olanzapine and risperidone. The 19th European College Neuropsychopharmacology, 16th-20th, September, 2006, Paris, France, S399. (Citation: European Neuropsychopharmacology, Volume 16, Supplement 4, Page S399; **ECNP Guided Tour Poster**)
38. Su KP\*, Huang CL, Hsu HB, Pariante C. A pilot crossover study on QTc interval associated with olanzapine and risperidone. The 25th Collegium Internationale Neuro-Psychopharmacologicum Congress, 9-13, July, 2006, Chicago, USA, S265.
39. Su KP\*, Wu PL, Pariante C. A cross-over study on safety of lipid profiles associated with olanzapine and risperidone. The 18th European College Neuropsychopharmacology, Oct. 22nd-26th, 2005, Amsterdam, Netherlands, S463. (Citation: The Journal of the European College of Neuropsychopharmacology, Volume 15 (2005), Supplement 3, Page S463)
40. Su KP, Chiu CC, Huang SY. Decreased duration of immobility in rats on omega-3 fatty acid diet than olive oil diet. The 24th Collegium Internationale Neuro-Psychopharmacologicum Congress, June 20-24, 2004, Paris, France, S363.
41. Su KP. Hypoalbuminemia in major depressive disorder, World Journal of Biological Psychiatry Volume 5, Supplement 1, S88. The 8th International Congress of Biological Psychiatry, 9 - 13 February, 2004, Sydney, Australia.
42. Su KP, Chiu CC, Huang SY. Hypoalbuminemia in patients with major depressive disorder compared with a dietary matched control group: a clinical meaning beyond malnutrition. The 16th European College Neuropsychopharmacology, Sep., 2003, Prague, Czech, S275.
43. Su KP, Chiu CC, Huang SY. Omega-3 fatty acids in major depressive disorder. The 58th annual meeting of the Society of Biological Psychiatry Association, May, 2003, San Francisco, California, U.S.A., S33.
44. Su KP, Chiu CC, Huang SY. Polyunsaturated fatty acid deficit in patients with bipolar mania. The 15th European College Neuropsychopharmacology, Oct., 2002, Barcelona, Spain, S244.
45. Su KP, Chiu CC, Huang SY. Omega-3 fatty acids in major depressive disorder. Fifth International Congress on Essential Fatty Acids and Eicosanoids, August 29 – September 2, 2002, Taipei Taiwan.

46. Su KP, Chiu CC, Huang SY. Omega-3 fatty acid monotherapy for a pregnant patient with major depressive disorder. Fifth International Congress on Essential Fatty Acids and Eicosanoids, August 29 – September 2, 2002, Taipei Taiwan.
47. Su KP, Shen WW, Huang SY. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. The 14th European College Neuropsychopharmacology, Istanbul, Turkey, Oct., 2001.
48. Su KP, Chen KP, Shen WW, and Tsai SYM. QTc Prolongation Associated with Sulpiride and Haloperidol Use: a Pilot Crossover-design Study. The 13th European College Neuropsychopharmacology, Munich, Germany, 2000, S311-S312.
49. Su KP, Huang SY, Yang HT, Hsu CF, Huang MC, Shen WW. Medication effects on omega-3 fatty acid levels in patients with major depressive disorder. The 40th Annual Meeting of the Society of Psychiatry, Nov. 2001, Taipei Taiwan, p. 303.
50. Su KP, Huang SY, Liu CH, Hsu CF, Chiu CC, Shen WW. Omega 3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. The 40th Annual Meeting of the Society of Psychiatry, Nov. 2001, Taipei Taiwan, p. 62.
51. Huang SY, Su KP, Liu CH, Yang HT, Shen WW, Hsu CF. The characteristics of diet in patients with major depressive disorder. The 40th Annual Meeting of the Society of Psychiatry, Nov. 2001, Taipei Taiwan, p. 304.
52. Chiu CC, Huang MC, Su KP, Huang SY, Liu CH, Yang HT, Chen CC. Omega-3 fatty acid levels on red blood cell membranes in patients with bipolar mania. The 40th Annual Meeting of the Society of Psychiatry, Nov. 2001, Taipei Taiwan, p. 302-.
53. Su KP, Hsu CF, Huang SY, Shen WW. Omega 3 Fatty Acids on the Treatment of a Pregnant Schizophrenic Patient. The 39th Annual Meeting of the Society of Psychiatry, R.O.C., Hualien, Taiwan, 2000.
54. Su KP, Chen KP, Shen WW, and Tsai SYM. QTc Prolongation Associated with Sulpiride and Haloperidol Use. The 39th Annual Meeting of the Society of Psychiatry, R.O.C., Hualien, Taiwan, 2000.
55. Hsieh WC, Shen WW, Pan CC, Su KP. Intensive Stress-Management Group Psychotherapy on Outpatients with Anxiety Disorders: A Pilot Demonstration. The 39th Annual Meeting of the Society of Psychiatry, R.O.C., Hualien, Taiwan, 2000.
56. Su KP, Hsu CY, Lane HY, Sung SM, Tsai SY. Antihistamine withdrawal delirium: a case report. The 38th Annual Meeting of the Society of Psychiatry, R.O.C., Kaohsiung, Taiwan, 1999.
57. Su KP, Hsu CY, Hong CT, Sung SM, Tsai SY. Diffuse cerebrovascular lesions presenting as delusional disorder – MRI-defined vascular delusion. The 38th Annual Meeting of the Society of Psychiatry, R.O.C., Kaohsiung, Taiwan, 1999.
58. Su KP, Yu JM, Yang TW, Tsai SY, Chen CC. Mentally Retarded Criminal Offenders in Northern Taiwan. The 38th Annual Meeting of the Society of Psychiatry, R.O.C., Kaohsiung, Taiwan, 1999.
59. Su KP, Lee YJ, Lee MB. Severe peripheral polyneuropathy and rhabdomyolysis in lithium intoxication. The 38th Annual Meeting of the Society of Psychiatry, R.O.C., Kaohsiung, Taiwan, 1999.
60. Su KP, Lane HY, Chang WH, Chen CC, Hu WH. Elevated plasma clozapine concentrations after phenobarbital discontinuation. The 37th Annual Meeting of the Society of Psychiatry, R.O.C., Tainan, Taiwan, 1998.